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INTRODUCTION

63
Since its introduction in 2011, NIPT has had a significant impact on prenatal care. In only four 64 years, NIPT has evolved into a standard option for high-risk pregnancies [1] . Content has also 65 evolved from exclusive T21 testing to include T18, T13, SCAs, and select microdeletions. This 66 'standard' content can be expected to detect 80-83% of chromosomal abnormalities detected by 67 karyotyping in a general screening population [2] [3] [4] , however this leaves a gap of approximately 68 17-20% of alternative chromosomal/sub-chromosomal abnormalities not detected. 69
Consequently, obtaining comprehensive information about the genetic makeup of the fetus 70 requires an invasive procedure. To overcome these limitations, NIPT should be extended to 71 cover the entire genome. However, it is challenging to maintain a very high specificity and 72 positive predictive value when interrogating all accessible regions in the genome [5] . In previous 73 reports, we have overcome these technical hurdles [6] . Furthermore, a recent study by Yin et al. 74 demonstrated feasibility for non-invasive genome-wide detection of sub-chromosomal 75 abnormalities [7] . In this report, we have improved the assay and the statistical methods to 76 enable comprehensive genome-wide detection of CNVs ≥7 Mb. We present the results of a 77 large blinded clinical study of more than 1200 samples including more than 100 samples with 78 common aneuploidies detectable by traditional NIPT and over 30 samples affected by sub-79 chromosomal CNVs. 80
METHODS
81
STUDY DESIGN 82
This blinded, retrospective clinical study included samples from women considered at increased 83 risk for fetal aneuploidy based on advanced maternal age ≥35, a positive serum screen, an 84 abnormal ultrasound finding, and/or a history of aneuploidy. Archived samples were selected for 85 inclusion in the study by an unblinded internal third party according to the requirements 86 documented in the study plan. The samples were then blind-coded to all operators and the 87 analysts who processed the samples. After sequencing, an automated bioinformatics analysis 88 was performed to detect whole chromosome aneuploidies and sub-chromosomal CNVs. The 89 results were compiled electronically and were reviewed by a subject matter expert who 90 assigned the final classification. This manual review mimics the process in the clinical 91 laboratory, where cases are reviewed by a laboratory director before a result is signed out. The 92 complete list of classification results was provided to the internal third party for determination of 93 concordance. Analyzed samples had confirmation of positive or negative events by either G-94 band karyotype or microarray findings from samples collected through either CVS or 95 amniocentesis. Circulating cell-free "fetal" DNA is believed to originate largely from placental 96 trophoblasts. Genetic differences between the fetus and the placenta can occur (e.g. confined 97 placental mosaicism), leading to discordance between NIPT results and cytogenetic studies on 98 amniocytes or postnatally obtained samples [8] . Results from CVS by chromosomal microarray 99 were thus considered the most accurate ground truth. Therefore, discordant results originating 100 from amniocytes (karyotype or microarray) were resolved by sequencing at high coverage (an 101 average of 226 million reads per sample). Sequencing depth has been shown as the limiting 102 factor in NIPT methods, with increased depth allowing improved detection of events in samples 103 with lower fetal fractions or improved detection of smaller events [9] . High coverage sequencing 104 has been used in multiple studies to unambiguously identify sub-chromosomal events ([6,10-105 12]) and was used here as a reference for performance evaluation in discrepant amniocentesis 106
samples. 107
Details of the sample demographics are described in Table 1 . Indications for invasive testing are 108 described in Table 2 . 109
SAMPLE COLLECTION
110
In total, 1222 maternal plasma samples had been previously collected using Investigational 111
Review Board (IRB) approved protocols (protocol numbers: Compass IRB #00508, WIRB 112 #20120148, Compass IRB #00351, Columbia University IRB #AAAN9002) with a small subset 113 (9 samples) comprising remnant plasma samples collected from previously consented patients 114 in accordance with the FDA Guidance on Informed Consent for In Vitro Diagnostic Devices 115
Using Leftover Human Specimens that are Not Individually Identifiable (25 April 2006). All 116 subjects provided written informed consent prior to undergoing any study related procedures. 117
LIBRARY PREPARATION, SEQUENCING, AND ANALYTICAL METHODS
118
Libraries were prepared and quantified as described by Tynan et al. [13] . To reduce noise and 119 increase signal, sequencing depth for this analysis was increased to target 32M reads per 120 sample. Sequencing reads were aligned to hg19 using Bowtie 2 [14] . The genome was then 121 partitioned into 50-kbp non-overlapping segments and the total number of reads per segment was determined, by counting the number of reads with 5' ends overlapping with a segment. 123
Segments with high read-count variability or low map-ability were excluded. The 50 kbp read-124 counts were then normalized to remove coverage and GC biases, and other higher-order 125 artifacts using the methods previously described in Zhao et al [6] . 126
The presence of fetal DNA was quantified using the regional counts of whole genome single-127 end sequencing data as described by Kim et al. [15] . 128 To further improve specificity of CNV detection, bootstrap analysis was performed as an 141 additional measure for the confidence of the candidate CNVs. The within sample read count 142 variability was compared to a normal population (represented by 371 euploid samples) and 143 quantified by bootstrap confidence level (BCL). In order to assess within sample variability, the 144 bootstrap resampling described below was applied to every candidate CNV.
GENOME-WIDE DETECTION OF ABNORMALITIES
For each identified segment within the CNV, the median shift of segment fraction from the 146 normal level across the chromosome was calculated. This median shift was then corrected to 147 create a read count baseline for bootstrapping. Next, a bootstrapped segment of the same 148 segment length as the candidate CNV was randomly sampled with replacement from the 149 baseline read counts. The median shift was then applied to this bootstrapped fragment. The 150 segment fraction of the bootstrapped fragment was calculated as follows: 151
This process was repeated 1000 times to generate a bootstrap distribution of segment fractions 152 for an affected population. A normal reference distribution was created based on the segment 153 fraction of the same location as the candidate CNV in 371 euploid samples. A threshold was 154 then calculated as the segment fraction that was at least 3.95 median absolute deviations away 155 from the median segment fraction of the reference distribution. Lastly, the BCL was calculated 156 as the proportion of bootstrap segments whose fractions had absolute z-statistics above the 157 significance threshold. 158
A whole chromosome or sub-chromosomal abnormality is detected as follows: where C is a predefined z-score cutoff that controls the tradeoff between sensitivity and 164 specificity. For this study C was 3 for chromosome 21 trisomy and monosomy, and 3.95 for all 165 other CNVs. The comparison |z CHR | ≥  |z CBS | is used to distinguish a whole chromosome event from a sub-chromosomal event.  denotes the type 1 error for misclassification of abnormalities 167 as an aneuploidy. Simulations (see supplemental methods for [6]) showed that  = 0.8 resulted 168 in a misclassification of abnormalities at close to 0%; as such, this value was used for this study. 169
RESULTS
170
The study comprised a total of 1222 maternal plasma samples. After unblinding, eleven 171 samples were excluded because they had no or insufficient karyotype or microarray information 172 (see Figure 1 ) and three samples were excluded because of confirmed mosaicism. 173
Forty-two (42) of the remaining 1208 samples were flagged as non-reportable using quality 174 criteria that had been established prior to analysis, leaving 1166 reportable samples for 175 analyses. Technical failure criteria included but were not limited to: low library concentration, low 176 raw autosomal counts, high GC bias, poor normalization, and high bin variability (see Figure 1) . 177
Biological failure criteria included low fetal fraction (less than 4%) and large maternal CNV 178 events. The most common reason for failure was low fetal fraction (n= 11). During review of the 179 data, one sample was signed out as T18 (and was included in the analyzed cohort), even 180 though it did not meet the autosomal count minimum. This sample had sufficient counts for the 181 determination of standard aneuploidies, but not sufficient counts for the detection of sub- 
T21, T18, and T13 Detection 189
Among the 1166 reportable samples, there were 85 T21 samples, 27 T18 samples, and 15 T13 190 samples (see Figure 1 ). All euploid, T21, T18, and T13 samples (determined by invasive 191 diagnostic procedures) were classified correctly by NIPT. One sample was classified by NIPT 192 as T21 but had a normal (46, XX) karyotype by amniocentesis (see Supplemental Table 1 ). This 193 discrepancy was adjudicated through high coverage 'uniplex' sequencing (typically with >180 194 million reads) according to our study plan (see Supplemental Figure 1D ). The sample showed 195 16.3% fetal fraction, but the gain of genetic material from chromosome 21 was concordant with 196 6.5% fetal fraction. This is suggestive of confined placental mosaicism, a relatively common 197 cause of discordant results between amniocyte results and CVS or placentally-derived cell free 198 DNA analysis [8] . Table 3 summarizes the performance for T21, T18, and T13. For T21, the 199 sensitivity was 100% (95% CI: 94.6%-100%) and the specificity was 100% (95% CI: 99.6%-200 100%). For T18, the sensitivity was 100% (95% CI: 84.4%-100%) and the specificity was 100% 201 (95% CI: 99.6%-100%). For T13, the sensitivity was 100% (95% CI: 74.7%-100%) and the 202 specificity was 100% (95% CI: 99.6%-100%). 203
SCA Detection
204
In the 1166 samples reportable for all chromosomal abnormalities, there were 21 samples that 205 were flagged as non-reportable specifically for SCA classification based on thresholds for the 206 chromosome X z-score and chromosome Y z-score as described by Mazloom et al. [19] . There 207 was also one additional sample with an apparent maternal XXX that was flagged as non-208 reportable for SCA because the maternal event distorted the sex chromosomal representation 209 to a degree that fetal events could not be classified. Among the remaining 1144 samples 210 reportable for SCAs, there were 7 discordant positives that were classified as normal (46, XX) 211 by karyotype and as XO by sequencing at 6-plex (see Supplemental Table 1 ). In all discordant 212 cases, the karyotype had been obtained from amniocyte samples. This phenomenon is well 213 described and may be attributed to varying levels of placental or maternal mosaicism [20] . 214
Uniplex sequencing confirmed 6 of the 7 XO samples. The 7 th sample had a non-reportable 215 result at uniplex coverage, hence the existing amniocentesis result was used as truth resulting 216 in one false positive assignment. Overall, the sensitivity for SCA was 100% (95% CI: 84.0%-217 100%) with a specificity of 99.9% (95% CI: 99.4%-100%) (see Table 3 ). 218
Genome Wide Detection of CNVs
219
The test was also designed to detect CNVs equal to or larger than 7 Mb (including whole 220 chromosome abnormalities other than T13, T18, T21, and SCAs); as well as select 221 Overall, the sensitivity for detection of whole chromosome and sub-chromosomal abnormalities 228 other than T13, T18, T21, and SCAs was 97.7% (95% CI: 86.2%-99.9%) and the specificity was 229 99.9% (95% CI: 99.4%-100%) (see Table 3 ). One case was clearly mosaic for T22 by both 230 standard coverage and uniplex sequencing (see Supplemental Table 1 and Supplement Figure  231 1E), but was classified as normal by microarray analysis. Because the invasive diagnosis came 232 from microarray analysis of cells derived from CVS, our study design considered this as the gold 233 standard, and this outcome was considered a discordant positive. Another case showed no gain 234 or loss of genetic material with both standard and uniplex sequencing for a sample that had a 235 46, XX, der(12)t(12;19)(p13.1;q13.1) karyotype (see Supplemental Figure 2B ). This outcome 236 was considered as a discordant negative given that the invasive procedure was CVS. A set of 7 237 samples were classified as full chromosomal trisomies, and because the karyotype or 238 microarray results were derived from amniocytes in these cases, uniplex sequencing was 239 performed for adjudication per the study design. The trisomy finding was confirmed in each case 240 by uniplex sequencing, and these findings were considered as concordant positives 241 (Supplemental Figure 1) . 242
In addition to the high accuracy demonstrated in the results, in some cases NIPT could also 243 provide clarification about the origin of extra genetic material when the G-banding pattern was 244 not sufficiently clear. In one case, the amniocyte karyotype finding, 46, XX, der(5)t(5;?)(p15.3;?), 245 indicated a deletion on chromosome 5 and a duplication of unknown origin (see Figure 3 ). NIPT 
DISCUSSION
253
Couples and families who are seeking prenatal information about the genetic health of their 254 baby have multiple options todayranging from non-invasive tests that screen for select 255 chromosomal abnormalities to invasive procedures including karyotype and microarray testing 256 that can deliver the most comprehensive genomic assessment. Current NIPT methods provide 257 information about a limited set of conditions, that typically include T21, T18, T13 and SCAs. In 258 this study we expand testing to the entire genome. The results demonstrate that high sensitivity 259
and specificity were maintained while adding genome-wide clinically relevant content. that these limitations can be overcome by using a genome-wide approach, as described here 266 and previously [6] . In this study we demonstrate that the test can provide excellent performance 267
for CNVs ≥7Mb and select microdeletions <7Mb, across the genome. 268
This study has two main limitations. Although we analyze 2-to 6-fold more samples with sub-269 An interesting observation in this study was the sometimes subjective nature of karyotyping. 280
When G-banding is used as an analytical method, the optical resolution is occasionally not 281 sufficient to determine the origin of additional genetic material, making a clinical interpretation 282 more difficult. These ambiguities are eliminated when using NIPT because the test requires 283 sequencing alignment to the genome before DNA gains and losses are determined. However, 284 G-banding will, for the foreseeable future, be the superior methodology to determine copy 285 number neutral structural changes. 286
In pregnancies that can benefit from additional information, this test provides more clinically 287 relevant results than previous NIPT options. However, its role as a follow-up test to abnormal 288 ultrasound findings or as a general population screen will likely be debated for the foreseeable 289 future. It has been argued that the incidence of clinically relevant sub-chromosomal CNVs could 290 be as high as 1.7% in a general population [25] , and early microarray data [26] indicate that as 291 many as 30% of sub-chromosomal CNVs could be >7Mb. In consequence, the incidence for 292 these large CNVs may be around 0.5% in the general population, substantially higher than the 293 incidence of T21. 294
In summary, this clinical study provides validation for an approach that extends the clinical 295 validity of cfDNA testing, now providing detection of T21, T18, T13, SCAs, fetal sex, and 296 genome-wide detection of sub-chromosomal and whole chromosomal abnormalities. Overall, 297 sub-chromosomal abnormalities and aneuploidies other than T13, T18, T21, and SCAs were 298 detected with a combined clinical sensitivity and specificity of 97.7% and 99.9%, respectively. 299
This enables comprehensive non-invasive chromosomal assessment that was previously 300 available only by karyotype, and in some cases, may clarify cryptic findings otherwise 301 identifiable only by microarray. 302 303
